Bioventus Inc. (BVS) vs Cullinan Therapeutics, Inc. (CGEM)
A side-by-side comparison of Bioventus Inc. and Cullinan Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BVS
Bioventus Inc.
$13.50HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
CGEM
Cullinan Therapeutics, Inc.
$17.24HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
Total return — BVS vs CGEM
growth of $100 · dividends reinvested · last 6yBVS -29.6% (-5.7%/yr)CGEM -58.2% (-13.5%/yr)BVS compounded faster over this window
BVS CGEM
BVS vs CGEM: by the numbers
- •CGEM is the larger company ($1.06B vs $915M market cap).
- •BVS is profitable (9.36% net margin) while CGEM runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | BVS | CGEM |
|---|---|---|
| P/E ratio | 17.53 | N/A |
| Forward P/E | 17.33 | N/A |
| P/S ratio | 1.57 | N/A |
| P/B ratio | 4.01 | 3.29 |
| EV / EBITDA | 10.73 | N/A |
| FCF yield | 10.31% | N/A |
Profitability
| Metric | BVS | CGEM |
|---|---|---|
| Gross margin | 68.00% | 0.00% |
| Operating margin | 10.63% | 0.00% |
| Net margin | 9.36% | 0.00% |
| ROE | 23.86% | -63.62% |
| ROIC | 11.37% | -68.64% |
Growth (annualized)
| Metric | BVS | CGEM |
|---|---|---|
| Revenue CAGR (5Y) | 11.82% | N/A |
| EPS CAGR (5Y) | -5.03% | N/A |
| FCF CAGR (5Y) | 43.36% | N/A |
| Total return CAGR (5Y) | -0.81% | -7.48% |
Frequently asked
- Is BVS or CGEM more profitable?
- BVS runs the higher net margin — BVS at 9.36% versus CGEM at 0.00%.
- How have BVS and CGEM total returns compared?
- Over the past 5 years, BVS delivered -0.81% and CGEM delivered -7.48% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bioventus P/E ratioBioventus ROECullinan Therapeutics ROEBioventus operating marginCullinan Therapeutics operating marginBioventus revenue growthCullinan Therapeutics revenue growthBioventus free cash flowCullinan Therapeutics free cash flow
Bioventus & Cullinan Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.